Late-stage cancer vaccines

Late-stage cancer vaccines

Company Product Description Indication Status Trial details
Accentia BiovaxID Vaccine containing tumor-specific idiotype protein from the patient's lymphoma cells and conjugated to Keyhole-Limpet- Hemocyanin (KLH), an adjuvant to stimulate an immune response Stage III-IV follicular non- Hodgkin's lymphoma(NHL) Ph III; compl enrollment in 07 Dosing: After completing PACE chemotherapy (prednisone, adriamycin, cyclophosphamide, etoposide) and achieving a complete remission, followed by a waiting period to reconstitute the immune system, patients who remain in remission are randomized to the active treatment arm to receive a series of 5 monthly idiotype vaccinations accompanied by

Read the full 979 word article

How to gain access

Continue reading with a
two-week free trial.